semaglutide p Compounded (GLP-1) 3 Month Supply – Vaylen Health Sem-P™ - Getz Pharma -

Setmelanotide was approved by the FDA in 2020 for obesity resulting from defects to the melanocortin signaling pathway, such as LEPR, PCSK1, or POMC deficiencies (69)

Tirzepatide trials produced even better results, with the SURMOUNT-1 trial showing 15-22.5 percent body weight reduction depending on dose

Wades Care First Weight management at Wades Care First is not a prescription handed over at the end of a short appointment

Typical criteria: BMI 30 (or 27 with hypertension, type 2 diabetes, sleep apnea, etc.) 3-6 months documented lifestyle efforts (diet and exercise in your medical record) No concurrent GLP-1 use (can't take Ozempic, Wegovy at same time) Step therapy (trying other medications first): Some plans require trying other weight loss drugs before approving Wegovy Renewal: Must show 5% weight loss to continue coverage For complete documentation checklists and PA preparation: Wegovy Prior Authorization Guide Your GLP-1 coverage, denied approved If Anthem denies your Wegovy, Honest Care can help you build a strong appeal with evidence-backed documentation